2028-2029 will see some of the biggest blockbusters on the market lose their exclusivity with up to $115bn of sales at risk across those two years. Realistically, of course, it won’t be as much as that, but there are some big decisions to be made by several big pharma players about how to fill these impending gaps. 

In this eBook, we look at the scale of the challenge facing the market and the action that needs to be taken. We also reveal our updated consensus forecasts to 2028, which show a new number one leading the market with a few surprise fallers on the big pharma leader board. 



There’s a patent winter coming

Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?

Bristol needs to get fresh

Move over Amgen – Bristol Myers Squibb now looks like the big biopharma group most in need of revitalisation.
The biggest pharma company in 2028 revealed

New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place as new blood replaces Humira.
Humira hands its crown to Keytruda

Where do the top-selling drugs sit in our 2028 reboot?